CNR1 and fatty liver disease: Additional drugs acting on CB1 receptors include AM6545, a CB1 neutral antagonist with a 10-20% brain/plasma ratio, able to reduce food intake and body weight and ameliorate hepatic steatosis, insulin sensitivity, and dyslipidemia in preclinical animal models [176,177].